Cantor Fitzgerald’s AN2 Therapeutics ANTX Stock Holding History

Cantor Fitzgerald’s Portfolio ANTX Stock Details ANTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-200,000	Closed	-$684K	–	327
2026 Q1	$684K	Buy	+200,000	New	+$413K	0.01%	196

Other funds holding ANTX

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Cantor Fitzgerald's ANTX Position: Q2 2026 in Review

Cantor Fitzgerald sold out of AN2 Therapeutics (ANTX) in Q2 2026, closing a stake of 200,000 shares — an estimated $684K sold.

Cantor Fitzgerald first reported a position in ANTX in Q1 2026 and held it in 1 quarter. The position peaked at $684K in Q1 2026. 66 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

Cantor Fitzgerald reported no remaining AN2 Therapeutics position as of Q2 2026 after selling out during the quarter.
Cantor Fitzgerald sold 200,000 AN2 Therapeutics shares in Q2 2026, an estimated $684K.
Cantor Fitzgerald first reported a position in AN2 Therapeutics in Q1 2026 and held it in 1 quarter.
Cantor Fitzgerald's AN2 Therapeutics position peaked at $684K in Q1 2026.
66 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on Cantor Fitzgerald's 13F filing for Q2 2026, filed 14 Aug 2026.